2025-09-14 - Analysis Report
Okay, here's a comprehensive analysis of SDGR (Schrodinger Inc.) based on the data you provided. The report is in English and includes quantitative data with brief analysis following each section.

---

## SDGR (Schrodinger Inc.) Stock Analysis

**Company Overview:** Schrödinger, Inc. is a company that develops software for drug discovery and materials science.

### 1. Performance vs. S&P 500 (VOO)

*   **SDGR Cumulative Return:** -55.97%
*   **VOO Cumulative Return:** 62.60%
*   **Absolute Divergence:** -118.57% (SDGR underperformed VOO by this amount)
*   **Relative Divergence:** -126.9 (on a scale where min = -128.2 and max = 278.2)
    *   *Interpretation:* SDGR has significantly underperformed the S&P 500. The relative divergence indicates that SDGR's performance is near the lowest end of its historical range relative to the S&P 500.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha   | Beta  | Cap(B) |
|------------|----------|-------|---------|-------|--------|
| 2020-2022  | -74.0%   | 68.9% | -91.0%  | 0.0   | 1.4    |
| 2021-2023  | -65.0%   | 68.9% | -85.0%  | -0.0  | 2.6    |
| 2022-2024  | 8.0%     | 72.4% | -18.0%  | -0.0  | 1.4    |
| 2023-2025  | -3.0%    | 74.0% | -57.0%  | -0.2 | 1.4    |

*   *Analysis:*
    *   **CAGR:** Compound Annual Growth Rate shows negative returns for most periods, except for 2022-2024.
    *   **MDD:** Maximum Drawdown is consistently high, indicating significant risk.
    *   **Alpha:**  The strongly negative Alpha suggests SDGR has underperformed its benchmark.
    *   **Beta:** Beta values close to 0 suggest low correlation with the S&P 500.

### 2. Recent Stock Price Movement

*   **Current Price:** $18.57
*   **Previous Close:** $18.78
*   **Price Change:** -1.12%
*   **5-Day Moving Average:** $18.88
*   **20-Day Moving Average:** $19.36
*   **60-Day Moving Average:** $20.30

*   *Analysis:* The stock is trading below all its moving averages (5, 20, and 60 days), indicating a short-term downtrend. The negative price change from the previous close further reinforces this bearish sentiment.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 31.99 (Approaching oversold territory)
*   **PPO:** -0.2066
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** -0.1 (Negative - indicating a short-term decline)
*   **Expected Return (%):** -4373.3%

*   *Analysis:*
    *   The RSI is approaching oversold territory, suggesting that the stock *may* be due for a bounce.
    *   The MRI is in the "Low Risk" range, which seems counterintuitive given the stock's performance. This may be due to the MRI calculation methodology and its insensitivity to company-specific risks.
    *   The Hybrid Signal suggests buying a small amount, but with caution due to the MRI, implying a weak buy signal.
    *   The Recent Relative Divergence Change confirms a short-term downward trend.
    *   **The extremely negative Expected Return suggests that based on current trends, SDGR is projected to significantly underperform the S&P 500 over a long-term (2+ year) investment horizon. This number is likely anomalous and should be interpreted with extreme caution.**
    *   The current price change of -1.12% does reflects a minor negative market sentiment.

### 4. Recent News & Significant Events

*   **[2025-09-11]** Schrödinger (SDGR): Evaluating Valuation as Market Sentiment Remains Quiet (Simply Wall St.)
*   **[2025-09-09]** Does Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect? (Zacks)
*   **[2025-08-27]** Schrödinger to Present at Morgan Stanley Global Healthcare Conference (Business Wire)
*   **[2025-08-15]** Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
*   **[2025-08-14]** Schrödinger Announces Discontinuation of SGR-2921 Program (Business Wire)

*   *Analysis:* The news is mixed. While some articles discuss potential rallies, others highlight valuation concerns and the discontinuation of a program (SGR-2921), which is generally a negative signal. The inducement grants announcement is generally neutral.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy (~1.38)
*   **Opinions:** 9
*   **Target Price (avg/high/low):** $28.11 / $33.00 / $19.00

*   *Analysis:*  Analysts are generally positive on the stock, with a "Strong Buy" consensus and a significant average target price above the current price.  However, the low target price is around the current price which needs attention.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue   |
|------------|-------|-----------|
| 2025-08-06 | -0.59 | 0.05 B$  |
| 2025-05-07 | -0.82 | 0.06 B$  |
| 2024-11-12 | -0.52 | 0.04 B$  |
| 2024-07-31 | -0.74 | 0.05 B$  |
| 2025-08-06 | -0.74 | 0.05 B$  |

*   *Analysis:*  The company has consistently reported negative EPS, indicating a lack of profitability. Revenue has been relatively stable, but not sufficient to offset expenses.

### 6. Financial Information: Revenue, Profitability, Capital, and Profitability

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.05B  | 47.77%        |
| 2025-03-31 | $0.06B  | 52.26%        |
| 2024-12-31 | $0.09B  | 72.61%        |
| 2024-09-30 | $0.04B  | 50.24%        |
| 2024-06-30 | $0.05B  | 66.20%        |

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-06-30 | $0.34B  | -12.59%   |
| 2025-03-31 | $0.37B  | -16.01%   |
| 2024-12-31 | $0.42B  | -9.54%    |
| 2024-09-30 | $0.45B  | -8.49%    |
| 2024-06-30 | $0.47B  | -11.40%   |

*   *Analysis:*
    *   While revenue varies, profit margins have been relatively strong. However, the high profit margins are not translating into overall profitability (as evidenced by the negative EPS and ROE).
    *   Equity has been declining, and ROE is consistently negative, reflecting poor returns on equity.

### 7. Overall Analysis & Summary

Schrodinger (SDGR) is a high-risk investment based on the provided data. While analysts have a "Strong Buy" consensus, the company's financial performance is concerning. It has significantly underperformed the S&P 500, has negative earnings, declining equity, and negative ROE. While profit margins are relatively high, they are not sufficient to offset expenses and generate overall profitability.

**Key Concerns:**

*   **Significant Underperformance:**  Trailing the S&P 500 by a large margin.
*   **Negative Earnings:**  Consistent losses.
*   **Declining Equity:**  Erosion of shareholder value.
*   **Program Discontinuation:** A negative signal regarding the company's pipeline.

**Potential Positives:**

*   **Analyst Sentiment:**  Strong Buy ratings may indicate potential upside.
*   **High Profit Margins:** If revenue can be scaled, profitability could improve.
*   **RSI Approaching Oversold:** *Potential* for a short-term bounce.
*   **Low Risk (MRI):** Market risk indicator suggests caution for investment

**Recommendation:**

Given the significant risks, a cautious approach is warranted. Any investment in SDGR should be considered highly speculative and a small portion of a diversified portfolio.  Further investigation into the reasons for the negative earnings and declining equity is strongly advised. The extremely negative Expected Return (while likely anomalous) also reinforces the need for caution.
